The major therapeutic strategy being used at present is ET with ERα antagonists and agents that reduce the production of estrogen to inhibit LBC progression by interfering with ERα signaling. The gene discussed is ESR1; the disease is CDH1-related diffuse gastric and lobular breast cancer syndrome.